 we report on our financial results for the fourth quarter and full year of 2020 and provide an outlook for the remainder of the year and beyond. 
 this is our first earnings conference call and our 2020 annual business update. in 2020, we grew our business by more than a factor of ten over the previous year and we added 52 program starts to the cumulative 43 starts we had at the end of 2019. Revenue in 2020 grew 20-fold over 2019 to $233 million. we achieved royalty revenue of $198 million and milestone payments of $15 million attributable to bamlanivimab, achieving milestones all the way from Phase 1 through two first commercial sale by Lilly in the United States. we also secured funding for and began work on the buildup of cMC and GMP manufacturing capabilities. 
 we ended the year with nearly $600 million in cash and over $200 million in accounts receivable. 
 this provides a strong cash position with which we will execute our plan for future growth.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in 